Parexel to lay off up to 125 transferred GSK employees


Parexel to lay off up to 125 transferred GSK employees

By Zachary Brennan

Beginning Sept. 30, Massachusetts-based CRO (contract research organization) Parexel will lay off as many as 125 of the 450 employees it brought on from GlaxoSmithKline (GSK) in North Carolina late last year, according to a North Carolina WARN report...

Some industry experts are doubting if consolidated companies can provide the same services as their former selves.

Dispatches from ChemOutsourcing

CMO consolidation: Do biopharma partners see any benefits?

By Zachary Brennan

As contract manufacturers continue to consolidate, some in the industry are questioning whether the resulting companies have the ability to offer the same services as the former individual companies. 

The acquisition will grow Chiltern's presence in the US.

Chiltern taps oncology expertise with Ockham acquisition

By Zachary Brennan

UK-based CRO Chiltern has agreed to acquire Ockham, a North Carolina-based full-service CRO, and the combined company will now compete with mid-sized CROs. Financial terms of the acquisition were not announced.

GPCM conference venue: Pestana Chelsea Bridge Hotel, London, UK

Dispatches from the GPCM Conference, London, UK

For big pharma, ten is the magic number of CMOs says ex-GSK Director

By Dan Stanton

Big pharma is moving towards strategic partnerships with CMOs, according to speakers at the Global Pharmaceutical Contract Manufacturing (GPCM) Conference, with the ideal number of partners being ten.

Eli Lilly's Kinsale site - manufacturing both small and large molecules

Exclusive Interview

Lilly focuses in-house as manufacturing becomes more complex

By Dan Stanton

Eli Lilly is maintaining greater in-house control as manufacturing processes become more complex, whilst MSD is leveraging external over-capacity to fulfil its needs, the firms told during a recent visit to Ireland.

Follow us


View more